{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T16:25:57Z","timestamp":1777739157919,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001449"],"award-info":[{"award-number":["UL1 TR001449"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10557-024-07563-3","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T06:01:43Z","timestamp":1715320903000},"page":"783-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discharge of Acute Coronary Syndrome Patients on Sub-Optimal Dual Anti-Platelet Therapy: A Single Center Experience"],"prefix":"10.1007","volume":"39","author":[{"given":"Jeffrey B","family":"Booker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J","family":"Nihart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J","family":"Campen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Medrano-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-533X","authenticated-orcid":false,"given":"James C","family":"Blankenship","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"7563_CR1","doi-asserted-by":"publisher","unstructured":"Harrington RA, Becker RC, Ezekowitz M et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513S-548S. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.513S","DOI":"10.1378\/chest.126.3_suppl.513S"},{"key":"7563_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2009;361:1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"7563_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.amjcard.2015.04.054","volume":"116","author":"HB Chen","year":"2015","unstructured":"Chen HB, Zhang XL, Liang HB, Liu XW, Zhang XY, Huang BY, Xiu J. Meta-analysis of randomized controlled trials comparing risk of major adverse cardiac events and bleeding in patients with prasugrel versus clopidogrel. Am J Cardiol. 2015;116:384\u201392. https:\/\/doi.org\/10.1016\/j.amjcard.2015.04.054","journal-title":"Am J Cardiol"},{"key":"7563_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/clc.23536","volume":"44","author":"W Chen","year":"2021","unstructured":"Chen W, Zhang C, Zhao J, et al. Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: a network meta-analysis. Clin Cardiol. 2021;44:488\u201394. https:\/\/doi.org\/10.1002\/clc.23536","journal-title":"Clin Cardiol"},{"key":"7563_CR5","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","volume":"79","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol. 2022;79:e21\u2013129. https:\/\/doi.org\/10.1016\/j.jacc.2021.09.006","journal-title":"J Am Coll Cardiol"},{"key":"7563_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic surgery (EACTS). Eur Heart J. 2018;39:213\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"7563_CR7","doi-asserted-by":"publisher","first-page":"e015990","DOI":"10.1161\/JAHA.119.015990","volume":"9","author":"S V\u00f6lz","year":"2020","unstructured":"V\u00f6lz S, Petursson P, Odenstedt J, et al. Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish coronary angiography and Angioplasty Registry. Journal of the American Heart Association. J Am Heart Assoc. 2020;9:e015990. https:\/\/doi.org\/10.1161\/JAHA.119.015990","journal-title":"J Am Heart Assoc"},{"key":"7563_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/imj.13041","volume":"46","author":"MB Yudi","year":"2016","unstructured":"Yudi MB, Clark DJ, Farouque O, et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J. 2016;46:559\u201365. https:\/\/doi.org\/10.1111\/imj.13041","journal-title":"Intern Med J"},{"key":"7563_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1753944712468627","volume":"7","author":"JJ DiNicolantonio","year":"2013","unstructured":"DiNicolantonio JJ, Serebruany VL. Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports. Ther Adv Cardiovasc Dis. 2013;7:5\u20139. https:\/\/doi.org\/10.1177\/1753944712468627","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"7563_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijcard.2014.02.028","volume":"173","author":"M Gaubert","year":"2014","unstructured":"Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol. 2014;173:120\u20131. https:\/\/doi.org\/10.1016\/j.ijcard.2014.02.028","journal-title":"Int J Cardiol"},{"key":"7563_CR11","doi-asserted-by":"publisher","unstructured":"Peasah SK, Mager D, Munshi KD, Huang Y, Henderson R, Swart EC, Neilson L, Good CB. Real-world use and outcomes of oral antiplatelets among patients with acute coronary syndrome: a retrospective cohort study. Drugs-Real World Outcomes. 2022 Mar;1:1\u20137. https:\/\/doi.org\/10.1007\/s40801-021-00283-2","DOI":"10.1007\/s40801-021-00283-2"},{"key":"7563_CR12","doi-asserted-by":"publisher","first-page":"e024835","DOI":"10.1161\/JAHA.121.024835","volume":"11","author":"AF Ozaki","year":"2022","unstructured":"Ozaki AF, Jackevicius CA, Chong A, et al. Hospital-level variation in ticagrelor use in patients with acute coronary syndrome. J Am Heart Assoc. 2022;11:e024835. https:\/\/doi.org\/10.1161\/JAHA.121.024835","journal-title":"J Am Heart Assoc"},{"key":"7563_CR13","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/cts.13596","volume":"16","author":"A Kumar","year":"2023","unstructured":"Kumar A, Lutsey PL, St. Peter WL, et al. Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013\u20132018. Clin Translation Sci. 2023;16:1886\u201397. https:\/\/doi.org\/10.1111\/cts.13596","journal-title":"Clin Translation Sci"},{"key":"7563_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.amjcard.2023.03.012","volume":"198","author":"EJ Wiens","year":"2023","unstructured":"Wiens EJ, Leon SJ, Whitlock R, Tangri N, Shah AH. Ticagrelor as compared to clopidogrel following percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2023;198:26\u201332. https:\/\/doi.org\/10.1016\/j.amjcard.2023.03.012","journal-title":"Am J Cardiol"},{"key":"7563_CR15","doi-asserted-by":"publisher","first-page":"e238585","DOI":"10.1001\/jamanetworkopen.2023.8585","volume":"6","author":"Y Wang","year":"2023","unstructured":"Wang Y, Cavallari LH, Brown JD, Thomas CD, Winterstein AG. Assessing the clinical treatment dynamics of antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention in the US. JAMA Netw Open. 2023;6:e238585. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.8585","journal-title":"JAMA Netw Open"},{"key":"7563_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43044-020-00128-3","volume":"73","author":"NB Senguttuvan","year":"2021","unstructured":"Senguttuvan NB, Sankaran R, Rajeev Y, et al. Effect of discontinuation of ticagrelor and switching-over to other P2Y12 agents in patients with acute coronary syndrome: a single-center real-world experience from India. Egypt Heart J. 2021;73:1\u20138. https:\/\/doi.org\/10.1186\/s43044-020-00128-3","journal-title":"Egypt Heart J"},{"key":"7563_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/jac5.1010","volume":"1","author":"AL Walker","year":"2018","unstructured":"Walker AL, Sorensen T, Gabriel PP, et al. Ticagrelor use in acute myocardial infarction: balancing evidence-based medicine with affordability. J Am Coll Clin Pharm. 2018;1:58\u201361. https:\/\/doi.org\/10.1002\/jac5.1010","journal-title":"J Am Coll Clin Pharm"},{"key":"7563_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijcard.2020.01.029","volume":"304","author":"BA Rodwin","year":"2020","unstructured":"Rodwin BA, Lu D, Giaimo A, et al. Patient and hospital characteristics associated with ticagrelor uptake in acute MI: an analysis of the chest Pain\u2013MI Registry. Internat J Card. 2020;304:14\u201320. https:\/\/doi.org\/10.1016\/j.ijcard.2020.01.029","journal-title":"Internat J Card"},{"key":"7563_CR19","doi-asserted-by":"publisher","unstructured":"Faridi KF, Garratt KN, Kennedy KF et al. Physician and hospital utilization of P2Y12 inhibitors in ST-segment\u2013elevation myocardial infarction in the United States: a study from the National Cardiovascular Data Registry\u2019s Research to Practice Initiative. Circulation: Cardiovasc Qual Outcomes. 2020;13:e006275. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.006275","DOI":"10.1161\/CIRCOUTCOMES.119.006275"},{"key":"7563_CR20","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.3390\/jcm12124094","volume":"12","author":"A Hammer","year":"2023","unstructured":"Hammer A, Krammel M, Aigner P, et al. The impact of preclinical high potent P2Y12 inhibitors on decision making at discharge and clinical outcomes in patients with acute coronary syndrome. J Clin Med. 2023;12:4094. https:\/\/doi.org\/10.3390\/jcm12124094","journal-title":"J Clin Med"},{"key":"7563_CR21","doi-asserted-by":"publisher","unstructured":"Aujoulat I, Jacquemin P, Rietzschel E et al. Factors associated with clinical inertia: an integrative review. Adv Med Ed Pract. 2014:141\u20137. https:\/\/doi.org\/10.2147\/AMEP.S59022","DOI":"10.2147\/AMEP.S59022"},{"key":"7563_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/03007995.2018.1469480","volume":"35","author":"JA Garc\u00eda-Mac\u00edas","year":"2019","unstructured":"Garc\u00eda-Mac\u00edas JA, Palazon-Bru A, Carbonell-Torregrosa M\u00c1, Navarro-Juan M, Gil-Guill\u00e9n VF. Therapeutic inertia in anti-platelet therapy in patients with a cardiovascular event attended in an emergency department. Curr Med Res Opin. 2019;35:455\u20139. https:\/\/doi.org\/10.1080\/03007995.2018.1469480","journal-title":"Curr Med Res Opin"},{"key":"7563_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/09537104.2020.1792871","volume":"32","author":"M Biswas","year":"2021","unstructured":"Biswas M, Kali MS, Biswas TK, Ibrahim B. Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel\/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Platelets. 2021;32:591\u2013600. https:\/\/doi.org\/10.1080\/09537104.2020.1792871","journal-title":"Platelets"},{"key":"7563_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","volume":"14","author":"M Galli","year":"2021","unstructured":"Galli M, Franchi F, Rollini F, et al. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev Clin Pharmacol. 2021;14:963\u201378. https:\/\/doi.org\/10.1080\/17512433.2021.1927709","journal-title":"Expert Rev Clin Pharmacol"},{"key":"7563_CR25","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","volume":"324","author":"SC You","year":"2020","unstructured":"You SC, Rho Y, Bikdeli B, et al. Association of Ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324:1640\u201350. https:\/\/doi.org\/10.1001\/jama.2020.16167","journal-title":"JAMA"},{"key":"7563_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","volume":"142","author":"EP Navarese","year":"2020","unstructured":"Navarese EP, Khan SU, Ko\u0142odziejczak M, et al. Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020;142:150\u201360. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046786","journal-title":"Circulation"},{"key":"7563_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/2048872614554108","volume":"4","author":"G Parodi","year":"2015","unstructured":"Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Euro Heart J: Acute Cardiovasc Care. 2015;4:555\u201360. https:\/\/doi.org\/10.1177\/2048872614554108","journal-title":"Euro Heart J: Acute Cardiovasc Care"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07563-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07563-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07563-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:11:04Z","timestamp":1757099464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07563-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7563"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07563-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3425525\/v1","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"20 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All studies were conducted with approval from the UNM Human Research Protections Office and Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"UNM Human Research Protections Office and Institutional Review Board confirmed that for this retrospective study, individual patient consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"No data belonging to individuals is included in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}